Enfusion (NYSE:ENFN) Releases Earnings Results, Misses Expectations By $0.02 EPS

Enfusion (NYSE:ENFN) posted its earnings results on Monday. The company reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02), Zacks reports. Enfusion had a return on equity of 6.67% and a net margin of 1.70%.

Enfusion Trading Down 1.0 %

ENFN opened at $11.36 on Tuesday. The company’s 50 day moving average is $10.91 and its 200-day moving average is $9.81. Enfusion has a 1-year low of $7.83 and a 1-year high of $11.80. The company has a market cap of $1.46 billion, a P/E ratio of 284.07, a PEG ratio of 1.85 and a beta of 0.96.

Insider Buying and Selling

In related news, CFO Bradley Herring sold 4,134 shares of Enfusion stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $10.13, for a total transaction of $41,877.42. Following the sale, the chief financial officer now directly owns 266,369 shares in the company, valued at $2,698,317.97. This trade represents a 1.53 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Oleg Movchan sold 2,771 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total transaction of $28,070.23. Following the completion of the transaction, the chief executive officer now owns 526,702 shares in the company, valued at $5,335,491.26. This trade represents a 0.52 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 35,566 shares of company stock worth $372,671 in the last ninety days. Company insiders own 36.44% of the company’s stock.

Wall Street Analysts Forecast Growth

ENFN has been the topic of a number of recent research reports. William Blair reaffirmed a “market perform” rating on shares of Enfusion in a research report on Monday, January 13th. Stifel Nicolaus raised their price target on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Finally, Piper Sandler raised their price target on shares of Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a research report on Monday, December 23rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $11.13.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.